Breakthroughs in CAR-T Therapy Offer Hope for Multiple Myeloma Patients
TL;DR Summary
A clinical trial involving 97 patients with incurable multiple myeloma has shown promising results, with a third of participants living years without detectable cancer after immunotherapy, raising hope for a potential cure for this deadly blood cancer.
- From No Hope to a Potential Cure for a Deadly Blood Cancer The New York Times
- Drug labeled ‘potential cure’ for multiple myeloma treating Phoenix-area patients AZFamily
- Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma | JNJ Stock News GuruFocus
- Cilta-Cel Boosts Survival Vs SOC Across Key Subgroups of R/R Multiple Myeloma OncLive
- Legend Biotech Reports Long-Term Progression-Free Survival Data for CARVYKTI® in Multiple Myeloma and Promising Early Results from New CAR-T Therapies in Solid Tumors Nasdaq
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 1 min read
Condensed
80%
185 → 37 words
Want the full story? Read the original article
Read on The New York Times